Loading patent…
AssigneesInstitut Pasteur, Centre National de la Recherche Scientifique (CNRS), Inserm (Institut National De La Sante Et De La Recherche Medicale)
InventorsPierre Bruhns, Odile Madeleine Richard-Le Goff, Patrick Evan England, Sylviane Hoos, Friederike Jonsson
Estimating the term…
The present invention relates to novel antibodies, in particular murine monoclonal antibodies, chimeric and humanized, that are able to block specifically the human IgG receptors FcγRIIIA (CD16A) and FcγRIIIB (CD16B) as well as the amino and nucleic acid sequences coding for such antibodies. The invention also comprises the use of such antibodies or of fragments thereof as a medicament for the preventive and/or therapeutic treatment of diseases involving CD16, like autoimmune diseases, inflammatory disorders, allergies and infections, without inducing any adverse effects. In particular, these antibodies and fragments can prevent or treat anti-drug idiopathic thrombocytopenic purpura (ITP), rheumatoid arthritis (RA) and autoimmune hemolytic anemia (ANA).
An antagonistic antibody against CD16 or an antigen-binding fragment thereof, said antibody comprising:
An antagonistic antibody against CD16 or an antigen-binding fragment thereof, said antibody comprising:
Dependencies are inferred from the claim text.